These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 37774433)

  • 1. Design, synthesis, in vitro and in silico evaluation of novel substituted 1,2,4-triazole analogues as dual human VEGFR-2 and TB-InhA inhibitors.
    Zawal AG; Abdel-Aziz MM; Elbatreek MH; El-Shanawani AA; Abdel-Aziz LM; Elbaramawi SS
    Bioorg Chem; 2023 Dec; 141():106883. PubMed ID: 37774433
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Novel benzenesulfonamides as dual VEGFR2/FGFR1 inhibitors targeting breast cancer: Design, synthesis, anticancer activity and in silico studies.
    Hassan RM; Ali IH; El Kerdawy AM; Abo-Elfadl MT; Ghannam IAY
    Bioorg Chem; 2024 Nov; 152():107728. PubMed ID: 39178704
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Design, Synthesis, In Vitro Anti-cancer Activity, ADMET Profile and Molecular Docking of Novel Triazolo[3,4-a]phthalazine Derivatives Targeting VEGFR-2 Enzyme.
    El-Helby AA; Sakr H; Ayyad RRA; El-Adl K; Ali MM; Khedr F
    Anticancer Agents Med Chem; 2018; 18(8):1184-1196. PubMed ID: 29651967
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Development of gallic acid formazans as novel enoyl acyl carrier protein reductase inhibitors for the treatment of tuberculosis.
    Saharan VD; Mahajan SS
    Bioorg Med Chem Lett; 2017 Feb; 27(4):808-815. PubMed ID: 28117201
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Synthesis, Biological Evaluation and Molecular Docking Studies of New Pyrazolines as an Antitubercular and Cytotoxic Agents.
    Lokesh BVS; Prasad YR; Shaik AB
    Infect Disord Drug Targets; 2019; 19(3):310-321. PubMed ID: 30556506
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Benzoxazole/benzothiazole-derived VEGFR-2 inhibitors: Design, synthesis, molecular docking, and anticancer evaluations.
    El-Helby AA; Sakr H; Eissa IH; Al-Karmalawy AA; El-Adl K
    Arch Pharm (Weinheim); 2019 Dec; 352(12):e1900178. PubMed ID: 31596514
    [TBL] [Abstract][Full Text] [Related]  

  • 7. New coumarin linked thiazole derivatives as antimycobacterial agents: Design, synthesis, enoyl acyl carrier protein reductase (InhA) inhibition and molecular modeling.
    Kassem AF; Sabt A; Korycka-Machala M; Shaldam MA; Kawka M; Dziadek B; Kuzioła M; Dziadek J; Batran RZ
    Bioorg Chem; 2024 Sep; 150():107511. PubMed ID: 38870705
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Novel benzothiazole-based dual VEGFR-2/EGFR inhibitors targeting breast and liver cancers: Synthesis, cytotoxic activity, QSAR and molecular docking studies.
    Abd El-Meguid EA; Naglah AM; Moustafa GO; Awad HM; El Kerdawy AM
    Bioorg Med Chem Lett; 2022 Feb; 58():128529. PubMed ID: 35007724
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Design, synthesis, molecular docking, and anticancer activity of benzoxazole derivatives as VEGFR-2 inhibitors.
    El-Helby AA; Sakr H; Eissa IH; Abulkhair H; Al-Karmalawy AA; El-Adl K
    Arch Pharm (Weinheim); 2019 Oct; 352(10):e1900113. PubMed ID: 31448458
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Design, synthesis, molecular docking, and anticancer evaluations of 1-benzylquinazoline-2,4(1H,3H)-dione bearing different moieties as VEGFR-2 inhibitors.
    El-Adl K; El-Helby AA; Sakr H; El-Hddad SSA
    Arch Pharm (Weinheim); 2020 Aug; 353(8):e2000068. PubMed ID: 32510731
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Identification of potent indolizine derivatives against Mycobacterial tuberculosis: In vitro anti-TB properties, in silico target validation, molecular docking and dynamics studies.
    Venugopala KN; Chandrashekharappa S; Deb PK; Al-Shar'i NA; Pillay M; Tiwari P; Chopra D; Borah P; Tamhaev R; Mourey L; Lherbet C; Aldhubiab BE; Tratrat C; Attimarad M; Nair AB; Sreeharsha N; Mailavaram RP; Venugopala R; Mohanlall V; Morsy MA
    Int J Biol Macromol; 2024 Aug; 274(Pt 2):133285. PubMed ID: 38925196
    [TBL] [Abstract][Full Text] [Related]  

  • 12. 4-Aryl-1,4-Dihydropyridines as Potential Enoyl-Acyl Carrier Protein Reductase Inhibitors: Antitubercular Activity and Molecular Docking Study.
    Venugopala KN; Deb PK; Pillay M; Chopra D; Chandrashekharappa S; Morsy MA; Aldhubiab BE; Attimarad M; Nair AB; Sreeharsha N; Kandeel M; Venugopala R; Mohanlall V
    Curr Top Med Chem; 2021; 21(4):295-306. PubMed ID: 33138763
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The first-in-class pyrazole-based dual InhA-VEGFR inhibitors towards integrated antitubercular host-directed therapy.
    Shaaban MM; Teleb M; Ragab HM; Singh M; Elwakil BH; A Heikal L; Sriram D; Mahran MA
    Bioorg Chem; 2024 Apr; 145():107179. PubMed ID: 38367430
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Design and synthesis of 9H-fluorenone based 1,2,3-triazole analogues as Mycobacterium tuberculosis InhA inhibitors.
    Suresh A; Srinivasarao S; Agnieszka N; Ewa AK; Alvala M; Lherbet C; Chandra Sekhar KVG
    Chem Biol Drug Des; 2018 Jun; 91(6):1078-1086. PubMed ID: 29063733
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Design and synthesis of thiourea-based derivatives as Mycobacterium tuberculosis growth and enoyl acyl carrier protein reductase (InhA) inhibitors.
    Doğan ŞD; Gündüz MG; Doğan H; Krishna VS; Lherbet C; Sriram D
    Eur J Med Chem; 2020 Aug; 199():112402. PubMed ID: 32417538
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Discovery of novel indolyl-1,2,4-triazole hybrids as potent vascular endothelial growth factor receptor-2 (VEGFR-2) inhibitors with potential anti-renal cancer activity.
    Al-Hussain SA; Farghaly TA; Zaki MEA; Abdulwahab HG; Al-Qurashi NT; Muhammad ZA
    Bioorg Chem; 2020 Dec; 105():104330. PubMed ID: 33038552
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Development of benzo[d]oxazol-2(3H)-ones derivatives as novel inhibitors of Mycobacterium tuberculosis InhA.
    Pedgaonkar GS; Sridevi JP; Jeankumar VU; Saxena S; Devi PB; Renuka J; Yogeeswari P; Sriram D
    Bioorg Med Chem; 2014 Nov; 22(21):6134-45. PubMed ID: 25282650
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Novel diaryl ether derivatives as InhA inhibitors: Design, synthesis and antimycobacterial activity.
    Abdelaziz OA; Othman DIA; Abdel-Aziz MM; Badr SMI; Eisa HM
    Bioorg Chem; 2022 Dec; 129():106125. PubMed ID: 36126606
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Identification of new anti-mycobacterial agents based on quinoline-isatin hybrids targeting enoyl acyl carrier protein reductase (InhA).
    Khaleel EF; Sabt A; Korycka-Machala M; Badi RM; Son NT; Ha NX; Hamissa MF; Elsawi AE; Elkaeed EB; Dziadek B; Eldehna WM; Dziadek J
    Bioorg Chem; 2024 Mar; 144():107138. PubMed ID: 38262087
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tryptanthrin Analogues as Inhibitors of Enoyl-acyl Carrier Protein Reductase: Activity against Mycobacterium tuberculosis, Toxicity, Modeling of Enzyme Binding.
    Duca G; Pogrebnoi S; Boldescu V; Aksakal F; Uncu A; Valica V; Uncu L; Negres S; Nicolescu F; Macaev F
    Curr Top Med Chem; 2019; 19(8):609-619. PubMed ID: 30834838
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.